Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy

Cancer Immunology Research

Volumn 3, Issue 9, 2015, Pages 1070-1081

  Ochi, Toshiki ^a   Nakatsugawa, Munehide ^a   Chamoto, Kenji ^a   Tanaka, Shinya ^a,b   Yamashita, Yuki ^a   Guo, Tingxi ^a,c   Fujiwara, Hiroshi ^d   Yasukawa, Masaki ^d   Butler, Marcus O ^a,c   Hirano, Naoto ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TAKARA BIO INC   (Japan)

^c UNIVERSITY OF TORONTO   (Canada)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA A24 ANTIGEN; T LYMPHOCYTE RECEPTOR; CMTWNQMNL PEPTIDE; HLA B ANTIGEN; HLA-A*24:02 ANTIGEN; HLA-B*57:01 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OLIGOPEPTIDE; WT1 PROTEIN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ARTICLE; CANCER GENE THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CROSS REACTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NEPHROBLASTOMA; NONVIRAL GENE THERAPY; T LYMPHOCYTE; THYMUS; ADOPTIVE IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOTOXICITY; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; JURKAT CELL LINE; METABOLISM; PROCEDURES; TRANSPLANTATION;

CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOTOXICITY, IMMUNOLOGIC; GENETIC ENGINEERING; GENETIC THERAPY; HLA-A24 ANTIGEN; HLA-B ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; MAP KINASE KINASE KINASES; OLIGOPEPTIDES; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; WT1 PROTEINS;

EID: 84962014123     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0222     Document Type: Article

References (50)

1. Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T cells in the thymus. Annu Rev Immunol 2012;30:95-114.
2. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009;9:833-44.
3. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:333-47.
4. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013;13:525-41.
5. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anticancer therapy. Curr Opin Immunol 2012;24:633-9.
6. Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013;20:1029-32.
7. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008.
8. Amir AL, D'Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010;115:3146-57.
9. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994;179:1155-61.
10. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, et al. T cell allorecognition via molecular mimicry. Immunity 2009;31:897-908.
11. Morice A, Charreau B, Neveu B, Brouard S, Soulillou JP, Bonneville M, et al. Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules. PLoS One 2010;5:e12120.
12. Rist M, Smith C, Bell MJ, Burrows SR, Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. Blood 2009;114:2244-53.
13. Matis LA, Longo DL, Hedrick SM, Hannum C, Margoliash E, Schwartz RH. Clonal analysis of themajor histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol 1983;130:1527-35.
14. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001;166:973-81.
15. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinityenhanced T cells in myeloma and melanoma. Blood 2013;122:863-71.
16. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013;36:133-51.
17. Miles JJ, Douek DC, Price DA. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011;89:375-87.
18. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006;6:883-94.
19. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000;13:829-40.
20. Nakatsugawa M, Yamashita Y, Ochi T, Tanaka S, Chamoto K, Guo T, et al. Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol 2015;194:3487-500.
21. Stadinski BD, Trenh P, Smith RL, Bautista B, Huseby PG, Li G, et al. A role for differential variable gene pairing in creating T cell receptors specific for unique major histocompatibility ligands. Immunity 2011;35:694-704.
22. Yokosuka T, Takase K, Suzuki M, Nakagawa Y, Taki S, Takahashi H, et al. Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J Exp Med 2002;195:991-1001.
23. Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, et al. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol 2003;170:5103-9.
24. Trautmann L, Labarriere N, Jotereau F, Karanikas V, Gervois N, Connerotte T, et al. Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol 2002;32:3181-90.
25. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009;27:5195-201.
26. Gulyas M, Dobra K, Hjerpe A. Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells. Differentiation 1999;65:89-96.
27. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol 1997;25:945-50.
28. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993;119:1329-41.
29. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006;19:804-14.
30. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003;17:1301-12.
31. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, et al. Transferred WT1-reactive CD8+T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013;5:174ra27.
32. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113:6541-8.
33. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, et al. Vaccinationwith synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116:171-9.
34. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885-90.
35. Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 2011;118:1495-503.
36. Nakatsugawa M, Hirohashi Y, Torigoe T, Inoda S, Kiriyama K, Tamura Y, et al. Comparison of speedy PCR-ssp method and serological typing of HLA-A24 for Japanese cancer patients. J Immunoassay Immunochem 2011;32:93-102.
37. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003;102:3530-40.
38. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, Neuberg D, et al. Engagement of CD83 ligand induces prolonged expansion of CD8+T cells and preferential enrichment for antigen specificity. Blood 2006;107:1528-36.
39. Imataki O, Ansen S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, et al. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8 (+) T cells. J Immunol 2012;188:1609-19.
40. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 2008;15:1411-23.
41. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S, et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006;12:2967-75.
42. Butler MO, Hirano N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev 2014;257:191-209.
43. Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, et al. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Anticancer Res 2012;32:5201-9.
44. Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol 2008;88:311-20.
45. Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, et al. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest 2015;125:157-68.
46. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013;5:197ra03.
47. Garcia KC. Reconciling views on T cell receptor germline bias for MHC. Trends Immunol 2012;33:429-36.
48. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 2008;26:171-203.
49. Dai S, Huseby ES, Rubtsova K, Scott-Browne J, Crawford F, Macdonald WA, et al. Crossreactive T Cells spotlight the germline rules for alphabeta T cellreceptor interactions with MHC molecules. Immunity 2008;28:324-34.
50. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008;180:6116-31.